Résultats: 17

    Grading of recommendations, assessment, development, and evaluation (GRADE): Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 Years

    Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for children aged 6 months­–­­4 years was presented to the Advisory Committee for Immunization Practices (ACIP) on ...

    The Moderna COVID-19 vaccine’s local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the older age group (ages 2 to 5 years) than the younger ag...

    The advisory committee on immunization practices’ recommendation for use of Moderna COVID-19 vaccine in adults aged ≥18 years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines: United States, february 2022

    MMWR recomm. rep; 71 (11), 2022
    The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...

    ACIP update to the evidence to recommendations for a Pfizer-BioNTech COVID-19 booster in children ages 5-11 years

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 82 million cases and more than 998,000 COVID-19-associated deaths have...

    Vaccine uptake in the general population

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan, which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisati...

    Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices: United States, December 2021

    MMWR recomm. rep; 71 (3), 2022
    On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...

    ACIP evidence to recommendations for use of moderna COVID-19 vaccine in children ages 6 months – 5 years and Pfizer-BioNTech COVID-19 vaccine in children ages 6 months – 4 years under an Emergency use authorization

    he emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 85 million cases and more than 1,000,000 COVID-19-associated deaths hav...